The FDA recently released a draft guidance document that provided an overview of the content and format of information sponsors should include in the “Indications and Usage” section of a drug label for drugs and biologics.
The FDA recently released a draft guidance document that provided an overview of the content and format of information sponsors should include in the “Indications and Usage” section of a drug label for drugs and biologics.
The document, entitled “Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products—Content and Format,” will apply to the Indications and Usage section for new drugs as well as new indications, or if the label of an already approved drug needs to be revised.
“The indications and usage section should clearly communicate the scope of the approved indication, including the population to which the determination of safety and effectiveness is applicable… In some cases, FDA’s expert reviewers may fairly and responsibly conclude, based on their scientific training and experience, that the available evidence supports approval of an indication that is broader or narrower in scope than the precise population studied,” the document reads.
In addition, the guidance discusses circumstances where it “may be appropriate to consider an indication for an adult population in an age group broader than the population that was studied.” This approach, however, is generally not applicable across pediatric populations or between adult and pediatric populations due to the Pediatric Research Equity Act.
The guidance is part of a series of guidances that the agency has put out or is developing in order to assist developers with the content and format of labeling for drug and biological products.
“FDA-approved labeling is the primary communication tool for providing information on the safe and effective use of drugs to the medical community,” Jacqueline Corrigan-Curay, MD, JD, director of the Office of Medical Policy in FDA’s Center for Drug Evaluation and Research, said in a statement. “This guidance provides recommendations for drafting the Indications and Usage section of the labeling, including a discussion of the scope of an indication and the inclusion of age groups in indications. We believe this guidance will help healthcare providers identify appropriate treatment options for their patients.”
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.